Retatrutide, a experimental dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising results in preliminary human studies. Current https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/